



Know *now*


if she is at risk for cervical cancer

Stock photo. Posed by model.

Now, 3 clinically validated tests bring greater diagnostic certainty

The molecular and biomarker-based tests in the Roche Cervical Cancer Portfolio bring greater diagnostic certainty to cervical cancer screening so the results you provide can guide clinicians and women along each step, removing ambiguity that can arise in current testing approaches.

Only the Roche Cervical Cancer Portfolio covers the entire spectrum of screening, triage, and diagnostic solutions



Test with confidence

The cobas® HPV test is designed to help minimize the chance of false negatives and provide screening accuracy for all high-risk HPV genotypes.

Internal cellular control – Monitors the presence of human cells and confirms reaction completion to prevent false-negative results.

3 results in 1 test – Yields 3 results (HPV 16, HPV 18, 12 high-risk HPV pooled) in 1 test run, eliminating the need to reflex and giving you the information needed to make important clinical decisions.

No cross-reactivity – Demonstrates no cross-reactivity with low-risk HPV genotypes, helping to ensure that a positive result is a true positive.

HPV DNA detection – DNA is present and needed for the replication of the virus, when viral infections occur.³ DNA-based testing is supported by 25 years of data following millions of women.

	Roche cobas HPV test ^{1,2}
Internal cellular control	✓
3 results in 1 test	✓
No cross-reactivity	✓
HPV DNA detection	✓

The cobas HPV test

- Clinically validated in 2 of the largest cervical cancer screening trials, the ATHENA Study¹ and IMPACT Trial²
- Supports safe and effective patient care by accurately identifying women at risk for cervical disease^{1,2}
- Evaluated and FDA-approved for ASC-US reflex, co-testing, and HPV primary screening

Screen with the cobas HPV test now and as you adopt future guidelines and screening options

To learn more, visit go.roche.com/cervicalsolutions

References: 1. cobas® HPV test. Package insert v17, US. Roche Diagnostics; 2018. 2. cobas® HPV for cobas® 6800/8800. Package insert v1, US. Roche Diagnostics; 2020. 3. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. *Vaccine*. 2012;30(suppl 5):F55-F70.

cobas and CINtec are trademarks of Roche. All other product names and trademarks are the property of their respective owners.

©2020. Roche. MC-US-08439

Roche Diagnostics Corporation
9115 Hague Road
Indianapolis, IN 46256